Envestnet Asset Management Inc. Purchases 6,033 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Envestnet Asset Management Inc. lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,047 shares of the biopharmaceutical company’s stock after purchasing an additional 6,033 shares during the period. Envestnet Asset Management Inc. owned 0.06% of Alnylam Pharmaceuticals worth $19,454,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Capital World Investors raised its holdings in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company’s stock worth $3,906,284,000 after buying an additional 92,101 shares during the last quarter. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock valued at $2,996,296,000 after buying an additional 98,303 shares during the period. Capital Research Global Investors lifted its holdings in Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock valued at $1,639,767,000 after purchasing an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock valued at $1,031,705,000 after purchasing an additional 1,245,195 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $577,941,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the business’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the transaction, the chief executive officer directly owned 48,948 shares of the company’s stock, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ALNY shares. Morgan Stanley decreased their price target on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating on the stock in a research note on Friday, April 11th. Needham & Company LLC increased their target price on shares of Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the stock a “buy” rating in a report on Thursday, June 26th. JPMorgan Chase & Co. raised their price target on shares of Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the company an “overweight” rating in a report on Wednesday. BMO Capital Markets increased their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an “outperform” rating in a research report on Tuesday, June 24th. Finally, Citigroup raised their price target on shares of Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the stock a “buy” rating in a research report on Friday, July 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $346.13.

Alnylam Pharmaceuticals Stock Up 3.8%

NASDAQ ALNY opened at $322.81 on Thursday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $333.70. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. The business’s fifty day simple moving average is $303.76 and its 200-day simple moving average is $270.33. The firm has a market cap of $42.09 billion, a PE ratio of -154.45 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts’ expectations of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The firm’s quarterly revenue was up 20.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.16) earnings per share. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.